Welcome to our dedicated page for Gritstone Bio news (Ticker: GRTSQ), a resource for investors and traders seeking the latest updates and insights on Gritstone Bio stock.
Gritstone Bio Inc. (GRTSQ) is a clinical-stage biotechnology leader developing novel immunotherapies targeting cancer and infectious diseases. This dedicated news hub provides investors and researchers with comprehensive updates on the company's scientific advancements and corporate developments.
Access timely announcements including clinical trial milestones, regulatory filings, and research collaborations. Our curated collection features press releases detailing neoantigen-targeted therapies like GRANITE, partnership announcements with pharmaceutical leaders, and financial disclosures essential for market analysis.
Bookmark this page for structured access to verified information about GRTSQ's immunotherapy platform, vaccine development progress, and strategic initiatives. Regularly updated to serve as your primary resource for tracking this innovator's journey in next-generation biotech solutions.
Gritstone bio (OTC: GRTSQ) reported updated Phase 2 data for GRANITE, its immunotherapy for first-line microsatellite stable colorectal cancer. The study showed a 27% relative risk reduction of progression or death with GRANITE versus control in all treated population, and a 50% relative risk reduction in the low ctDNA subgroup. As of October 2024, 28% of GRANITE patients and 13% of control patients remain progression-free. The company filed for Chapter 11 bankruptcy on October 10, 2024, and is pursuing bidders for its assets, with a bid deadline of December 4, 2024. Overall survival data is expected in 2H 2025.
FAQ
What is the current stock price of Gritstone Bio (GRTSQ)?
What is the market cap of Gritstone Bio (GRTSQ)?
